Drug intelligence / Profile preview

BJTJ-0053

Development stage: Preclinical
Lead developer: Beijing Tuobixi Pharmaceutical

Overview

BJTJ-0053 is an investigational drug candidate being developed by Beijing Tuobixi Pharmaceutical in collaboration with Meiji for the treatment of heart failure. As of early 2024, the program is in the pre-clinical stage of development. Specific details regarding its molecular target, modality, and mechanism of action have not been publicly disclosed in available pipeline documentation. The candidate is part of a series of BJTJ-coded compounds developed through the partnership between the Chinese firm Beijing Tuobixi and the Japanese company Meiji.

Beyond the preview

Go deeper on BJTJ-0053.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BJTJ-0053.

Explore the full profile